Ravulizumab

Pre-clinicalActive

1 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Paroxysmal Nocturnal Haemoglobinuria

Conditions

Paroxysmal Nocturnal Haemoglobinuria

Trial Timeline

Feb 6, 2025 → Aug 1, 2028

NCT ID

NCT06633536

About Ravulizumab

Ravulizumab is a pre-clinical stage product being developed by AstraZeneca for Paroxysmal Nocturnal Haemoglobinuria. The current trial status is active. This product is registered under clinical trial identifier NCT06633536. Target conditions include Paroxysmal Nocturnal Haemoglobinuria.

What happened to similar drugs?

0 of 20 similar drugs in Paroxysmal Nocturnal Haemoglobinuria were approved

Approved (0) Terminated (4) Active (16)

🔄Crovalimab + EculizumabChugai PharmaceuticalPhase 3

🔄EculizumabAstraZenecaPhase 3

🔄DanicopanAstraZenecaPhase 3

🔄Iptacopan (LNP023)NovartisPhase 3

🔄IptacopanNovartisPhase 3

🔄LNP023 + Eculizumab + RavulizumabNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07399730	Pre-clinical	Recruiting	Apr 1, 2026	Dec 31, 2030	Atypical Hemolytic Uremic Syndrome
NCT06909253	Pre-clinical	Recruiting	May 15, 2025	Dec 31, 2029	Myasthenia Gravis, Generalized
NCT06633536	Pre-clinical	Active	Feb 6, 2025	Aug 1, 2028	Paroxysmal Nocturnal Haemoglobinuria

Competing Products

20 competing products in Paroxysmal Nocturnal Haemoglobinuria

See all competitors

Product	Company	Stage	Hype Score
Crovalimab + Eculizumab	Chugai Pharmaceutical	Phase 3	44
Crovalimab + Placebo	Chugai Pharmaceutical	Phase 1/2	36
Crovalimab + Eculizumab	Chugai Pharmaceutical	Phase 3	44
Eculizumab	AstraZeneca	Phase 3	40
Danicopan	AstraZeneca	Phase 3	47
LNP023	Novartis	Pre-clinical	33
Iptacopan (LNP023)	Novartis	Phase 3	40
iptacopan	Novartis	Phase 2	35
LNP023	Novartis	Phase 2	35
Iptacopan	Novartis	Pre-clinical	30
Iptacopan	Novartis	Phase 3	40
LNP023 + Eculizumab + Ravulizumab	Novartis	Phase 3	40
LNP023	Novartis	Phase 3	47
LFG316 + LNP023	Novartis	Phase 2	35
Iptacopan	Novartis	Phase 3	44
Crovalimab	Roche	Phase 3	44
ABP 959 + Eculizumab	Amgen	Phase 3	40
Pegcetacoplan	Swedish Orphan Biovitrum	Pre-clinical	33
BMS-919373 + Placebo (Matching with BMS-919373)	Bristol Myers Squibb	Phase 2	27
Humanized anti-Factor Bb monoclonal antibody + Placebo	Sanofi	Phase 1	29